Oncolytics Biotech (NASDAQ:ONCY) Stock Rating Upgraded by Raymond James

Oncolytics Biotech (NASDAQ:ONCY) was upgraded by Raymond James to a “moderate buy” rating in a research report issued to clients and investors on Thursday,Zacks.com reports. Raymond James also issued estimates for Oncolytics Biotech’s Q4 2024 earnings at ($0.09) EPS, FY2024 earnings at ($0.32) EPS, Q1 2025 earnings at ($0.09) EPS and FY2025 earnings at ($0.34) EPS.

Other research analysts have also recently issued research reports about the stock. HC Wainwright reissued a “buy” rating and set a $5.00 price target on shares of Oncolytics Biotech in a research report on Thursday. Leede Financial cut shares of Oncolytics Biotech from a “strong-buy” rating to a “moderate buy” rating in a research report on Wednesday.

Oncolytics Biotech Trading Down 3.0 %

Shares of ONCY stock opened at $0.98 on Thursday. The company’s 50-day moving average price is $1.09 and its 200-day moving average price is $1.06. The stock has a market cap of $75.53 million, a price-to-earnings ratio of -3.63 and a beta of 1.69. Oncolytics Biotech has a twelve month low of $0.84 and a twelve month high of $1.75.

Institutional Trading of Oncolytics Biotech

A hedge fund recently bought a new stake in Oncolytics Biotech stock. Virtu Financial LLC acquired a new stake in Oncolytics Biotech Inc. (NASDAQ:ONCY) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 51,889 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned 0.07% of Oncolytics Biotech at the end of the most recent quarter. Institutional investors and hedge funds own 6.82% of the company’s stock.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.